-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Piper Sandler Upgrades Aligos Therapeutics to Overweight, Raises Price Target to $3

Benzinga · 01/06/2023 09:01
Piper Sandler analyst Yasmeen Rahimi upgrades Aligos Therapeutics (NASDAQ:ALGS) from Neutral to Overweight and raises the price target from $2 to $3.